A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Latest Information Update: 05 May 2022
At a glance
- Drugs Cabozantinib (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms CELESTIAL
- Sponsors Exelixis
- 26 Apr 2022 Results of an analysis compared the impact of cabozantinib versus placebo on health-related quality of life published in the European Journal of Cancer
- 09 Apr 2022 Results OF retrospective analysis of the CELESTIAL, evaluating for outcomes in patients who had Child-Pugh B cirrhosis at Week 8, published in the BMC Cancer
- 22 Nov 2021 Results from aggregate data of second-line cabozantinib from the CELESTIAL trial and other real world study of regorafenib, published in the Journal of Cancer Research and Clinical Oncology